ArticleFrontiers in pediatrics2026
Impact of standardized fortified donor human milk on growth parameters and biomarkers in preterm very low birth weight infants: a single-center propensity score-matched analysis.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the short-term clinical application effects of standardized fortified donor human milk (SF-DHM) in preterm very low birth weight (VLBW) infants, with a focus on its impact on growth parameters and relevant biomarkers, in order to provide scientific evidence for nutritional intervention strategies in cases of insufficient maternal milk supply. Methods: A retrospective single-center study design was adopted. A total of 80 preterm VLBW infants hospitalized in the Neonatal Intensive Care Unit (NICU) of our hospital from January 2022 to March 2025 were included. Based on propensity score matching (PSM), infants were 1:1 matched according to variables such as sex, gestational age at birth, birth weight, and severity of illness, resulting in 40 infants in the control group and 40 in the observation group. The control group received conventional feeding based on maternal milk supplemented with formula as needed; the observation group received SF-DHM as the main enteral nutritional source after standardized nutritional fortification. The two groups were compared in terms of in-hospital growth parameters (weight gain velocity, head circumference growth velocity, length growth velocity, length of hospital stay, and incidence of extrauterine growth restriction at discharge), nutritional biomarkers [prealbumin (PA), albumin (ALB), total protein (TP)], inflammatory markers [interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α)], immune function markers (CD4+, CD8+, CD4+/CD8+), feeding tolerance, and incidence of complications. Results: There were no significant differences in baseline characteristics between the two groups after matching ( Conclusion: SF-DHM offers significant benefits in promoting growth, improving nutritional status, reducing inflammation, and enhancing immune function in preterm VLBW infants with limited nutritional support. As a safe, feasible, and effective enteral nutrition strategy, SF-DHM holds broad clinical application potential in NICU settings and is recommended for prioritized use in the nutritional management of preterm infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.